drugset / Trial / NCT04925557
Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
Non-randomizedParallel-groupSingle-blindDiagnostic
Summary
To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain.
Timeline
- Start
- 2021-11-13
- Primary completion
- 2023-06-01
- Completion
- 2023-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mayzent | Unknown | — | — |
| Comparator | Ocrelizumab | Monoclonal antibody | — | — |